Bio

Thomas Rose is an exceptionally experienced attorney who concentrates his practice on U.S. cross-border securities and corporate law matters. With a particular focus on U.S.-Canada activity, every year he and his team advise clients with respect to financing transactions totaling billions of dollars – regularly landing them among the top performers on Thomson Reuters’ annual league tables and recently earning the “Pharmaceutical Deal of the Year” Atlas Award from Global M&A Network. Tom’s services adapt and grow along with the needs of his clients. He represents U.S. and foreign issuers and investment banks in a broad range of public and private financings, including financings under the U.S.-Canada Multijurisdictional Disclosure System (MJDS), other cross-border public offerings, and U.S.-foreign private placements (including Rule 144A, Regulation D, and Regulation S offerings). Tom also advises U.S. and foreign issuers with respect to the U.S. securities and corporate law aspects of mergers and acquisition transactions, including portfolio company roll-ups, as well as in connection with litigation arising from such deals. Tom counsels U.S. and foreign issuers in connection with initial listings on the New York Stock Exchange (NYSE), the NYSE MKT, and the Nasdaq Stock Market (NASDAQ). He also helps clients ensure compliance with ongoing U.S. reporting and corporate governance requirements under U.S. federal securities laws and exchange rules, and acts as a principal American liaison (PAL) on the over-the-counter (OTC) international markets.